Amylyx Pharmaceuticals Inc. Common Stock Earnings Recaps
Q3 2025
Nov 8, 2025
Amylyx Pharmaceuticals recorded significant progress in Q3 2025, highlighted by the continued advancement of its lead drug avexitide for post-bariatric hypoglycemia, while strengthening its financial position with a cash balance of $344 million.
Key takeaways
- Avexitide, granted FDA breakthrough therapy designation, aims to address the unmet need in post-bariatric hypoglycemia with a pivotal Phase III trial set to complete recruitment by Q1 2026.
- Cash position strengthened to $344 million following a successful public offering, positioning the company for a potential drug launch in 2027.
- Positive participant engagement and motivation reported in clinical trials, reinforcing the significant demand for effective treatment options.
- AMX0035 for Wolfram syndrome and AMX0114 for ALS remain on track, with pivotal study plans and preliminary data expected in the coming year.